GlassScriptPhysician profile
Sydney S Walker
NPI 1740910934
$3,006.89
in general payments reported to CMS, 2019-2025
32 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $383 · 2023: $1,412 · 2024: $718 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $478.62 | 2023-2025 | |
| Amgen INC. | $367.01 | 2024-2025 | Repatha, Repatha |
| Novo Nordisk INC | $316.64 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $220.87 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $215.60 | 2022-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $212.30 | 2022-2024 | |
| Edwards Lifesciences Corporation | $175.96 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $112.21 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $106.89 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.67 | 2022-2023 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $88.51 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $77.54 | 2024-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $67.45 | 2024-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $43.95 | 2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $38.09 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $37.52 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.75 | 2022-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $34.77 | 2023 | Verquvo, Belsomra |
| Genzyme Corporation | $33.03 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.82 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $27.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.42 | 2023 | |
| Corium, LLC | $24.77 | 2023 | Adlarity |
| Astellas Pharma US INC | $22.58 | 2023 | Veozah |
| Scpharmaceuticals INC. | $19.42 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.36 | 2023 | Amvuttra |
| Antares Pharma, INC. | $15.94 | 2023 | Nocdurna, Xyosted, Tlando |
| Janssen Pharmaceuticals, INC | $15.21 | 2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $14.76 | 2022 | |
| Halozyme INC | $13.51 | 2023 | |
| Nevro Corp. | $13.30 | 2022 | |
| Mayne Pharma Commercial LLC | $7.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.